GlassScriptPhysician profile
Stephanie C Grim
NPI 1124066980
$2,435.45
in general payments reported to CMS, 2019-2025
32 companies · $262 in 2025
The $262 reported for 2025 was more than what 81% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $265 · 2021: $384 · 2022: $192 · 2023: $568 · 2024: $451 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,282.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $406.64 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $324.40 | 2021-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $178.59 | 2019-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Kaleo, INC. | $169.55 | 2019-2021 | |
| Sanofi Pasteur INC. | $138.25 | 2019-2025 | |
| Corium, LLC | $137.73 | 2022-2024 | Azstarys |
| Ultragenyx Pharmaceutical INC. | $112.49 | 2020-2023 | |
| Seqirus USA INC | $105.73 | 2022-2024 | Flucelvax, Flucelvax Quadrivalent |
| Tris Pharma INC | $100.26 | 2020-2025 | Dyanavel Xr |
| Sobi, INC | $96.38 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $73.35 | 2023-2025 | |
| Verrica Pharmaceuticals INC. | $60.88 | 2024-2025 | Ycanth |
| Nestle Healthcare Nutrition INC. | $55.23 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $54.65 | 2023-2024 | Flumist Quadrivalent |
| Alk-Abello, INC | $50.75 | 2023 | Grastek, Ragwitek, Odactra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $38.23 | 2024-2025 | Voxzogo 1.2mg |
| Cranial Technologies, INC | $35.93 | 2024-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $29.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.12 | 2020-2021 | |
| Abbvie INC. | $24.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.78 | 2019 | |
| Mylan Pharmaceuticals INC. | $23.01 | 2019 | |
| Biomerieux INC | $20.00 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Acadia Pharmaceuticals INC | $19.89 | 2024 | Daybue |
| Shire North American Group INC | $19.83 | 2019 | |
| Sarepta Therapeutics, INC. | $19.34 | 2020 | |
| Mission Pharmacal Company | $17.72 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $15.43 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.33 | 2022 | |
| Glaxosmithkline, LLC. | $15.00 | 2023 | Bexsero |
| Teva Pharmaceuticals USA, INC. | $12.99 | 2019 | |
| Adlon Therapeutics L.P. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Grim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.